Population
Dysgenic (CaV1.1-null) myotubes reconstituted with either CaV1.1a or CaV1.1e, and a chimeric CaV1.1e construct
Comparison
L-type current modulators and substitution of… vs CaV1.1a and unmodulated state
Design
Preclinical
Authors
Loading...
Supports CaV1.1e as a drug target in myotonic dystrophy; leaves open clinical translation pending human studies.
CaV1.1e behaves like other L-type calcium channels pharmacologically and is a potential drug target for myotonic dystrophy due to its inhibition by nifedipine.
Benedetti et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: